Definium Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-237.54	-183.79	-108.68	-95.73	-56.8	-93.04
Depreciation & Amortization	-	-	0.53	3.16	3.18	2.62
Stock-Based Compensation	23.8	20.1	16.91	15.49	13.71	42.72
Other Adjustments	52.83	22.7	15.45	6.43	-6.45	-1.16
Changes in Accounts Payable	4.86	3.34	-2.13	2.03	-2.06	1.28
Changes in Accrued Expenses	10.28	5.96	3.1	5.32	-0.42	4.63
Changes in Other Operating Activities	2.21	0.14	-4.32	-1.06	-1.31	-2.88
Operating Cash Flow	-144.77	-131.56	-79.13	-64.37	-50.14	-45.82
Purchases of Investments	-105.9	-268.36	-	-	-	-
Proceeds from Sale of Investments	141.88	116.75	-	-	-	-
Payments for Business Acquisitions	-	-	-	-	-	-0.3
Investing Cash Flow	52.85	-151.61	-	-	-	-0.3
Long-Term Debt Issued	21	42	10	15	-	-
Long-Term Debt Repaid	-11	-22	-	-	-	-
Net Long-Term Debt Issued (Repaid)	10	20	10	15	-	-
Issuance of Common Stock	9.11	263.66	259.97	7.69	43.21	98.82
Repurchase of Common Stock	-	-	-0.05	-	-0.41	-
Net Common Stock Issued (Repurchased)	9.11	263.66	259.91	7.69	42.8	98.82
Other Financing Activities	-0.45	-16.39	-16.72	-0.84	16.25	-
Financing Cash Flow	271.58	267.27	253.2	21.85	59.05	98.82
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	-0.01	-0.03	0.08	-0.31	0.74
Net Cash Flow	179.66	-15.9	174.04	-42.44	8.6	53.45
Free Cash Flow	-144.77	-131.56	-79.13	-64.37	-50.14	-45.82
Free Cash Flow Per Share	-1.52	-1.47	-1.12	-1.64	-1.62	-1.67
Levered Free Cash Flow	-210.2	-154.36	-101.5	-71.29	-57.4	-87.38
Unlevered Free Cash Flow	-176.02	-156.87	-106.73	-84.42	-66.93	-87.05